Editas Medicine, Inc. (EDIT) Given Consensus Rating of “Hold” by Analysts
Editas Medicine, Inc. (NASDAQ:EDIT) has received an average recommendation of “Hold” from the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $27.02.
Several analysts have issued reports on the company. Zacks Investment Research cut Editas Medicine from a “buy” rating to a “hold” rating in a report on Monday. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a report on Tuesday, July 18th. Cann restated a “hold” rating on shares of Editas Medicine in a report on Thursday, August 10th. Barclays PLC assumed coverage on Editas Medicine in a report on Wednesday, September 6th. They issued an “overweight” rating and a $28.00 target price for the company. Finally, Cowen and Company restated a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/14/editas-medicine-inc-edit-given-consensus-rating-of-hold-by-analysts.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. IHT Wealth Management LLC purchased a new position in shares of Editas Medicine during the 2nd quarter worth $107,000. Royal Bank of Canada grew its holdings in shares of Editas Medicine by 4.1% during the 2nd quarter. Royal Bank of Canada now owns 9,364 shares of the company’s stock worth $157,000 after purchasing an additional 372 shares during the period. Bank of America Corp DE grew its holdings in shares of Editas Medicine by 72.2% during the 1st quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after purchasing an additional 2,489 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in shares of Editas Medicine by 8.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 42,150 shares of the company’s stock worth $941,000 after purchasing an additional 3,249 shares during the period. Finally, ProShare Advisors LLC grew its holdings in shares of Editas Medicine by 18.9% during the 2nd quarter. ProShare Advisors LLC now owns 24,211 shares of the company’s stock worth $406,000 after purchasing an additional 3,857 shares during the period. Institutional investors and hedge funds own 67.17% of the company’s stock.
Shares of Editas Medicine (EDIT) opened at $24.68 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 10.12 and a quick ratio of 10.12. Editas Medicine has a twelve month low of $13.12 and a twelve month high of $29.20.
Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.04). The company had revenue of $6.28 million during the quarter, compared to analysts’ expectations of $2.66 million. Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.19%. The firm’s quarterly revenue was up 553.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.59) earnings per share. equities analysts anticipate that Editas Medicine will post -2.86 EPS for the current fiscal year.
About Editas Medicine
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.